NASDAQ: MMSI · Medical Instruments & Supplies

Merit Medical Systems (MMSI) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Merit Medical Systems (MMSI) at $82.63 a share. The stock last closed at $86.35, which puts the model's fair value 4.3% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Merit Medical Systems, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$82.63midpoint of 2,000 simulations
Last close$86.35NASDAQ: MMSI
Gap to fair value-4.3%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $82.63, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $86.35 is 4.3% above it: Fairly valued, on a high evidence grade.

What's nextNext report on 23 Feb 2027. Options prices imply a move of about 9% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give MMSI?

The calibrated range for MMSI over 63 trading days is $77.63 to $96.57. It sits around the last close, and its width comes from the volatility that MMSI's own options imply (32% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $63.73 to $105.86. In 44% of the simulations the fair value came out above the price the model ran on.

$45.28$148.42
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $82.63. Dashed line: the last close, $86.35.

Faircurve Insights · 14 Nov 2026

Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing and worldwide commercialisation of disposable medical products. It was first valued by Faircurve on 11 Jul 2026.

The model's fair value on the run of 14 Nov 2026 is $82.63 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $82.83, so the fair value moved -0.2%. The calibrated range over 63 trading days is $78.45 to $96.14, built from the volatility the stock's own options imply. The range is calibrated weekly against realised prices, using 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. The grade looks at input completeness, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.

Faircurve's model gives the company an overall quality score of 66 out of 100, measured against comparable companies. Earnings quality is the highest factor at 78, with FCF / net income of 1.28x against a peer median of 1.16x. Balance sheet scores 72, with net debt / EBITDA of 0.84x against a peer median of 2.08x. Capital discipline scores 39, with net buybacks at 0.0% of market value, the same as the peer median. The model compares the company with ICU Medical, Teleflex, AptarGroup, Avantor, Repligen, The Cooper Companies and Baxter, and with Envista, which has no verdict on this date.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does MMSI report earnings, and how has the stock reacted?

Merit Medical Systems's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 7.5% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. MMSI's 30 day implied volatility works out to about 9.3% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across MMSI's last 8 reports, ignoring direction, was 3.7%.

0%5%10%15%no quote2.9%30 Oct '24no quote3.0%25 Feb '25no quote2.4%30 Jul '25no quote7.6%30 Oct '25no quote2.9%24 Feb '26no quote4.4%30 Apr '269.2%5.2%30 Jul '2611.7%6.5%29 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in MMSI

5%10%15%20%25%29 Oct '26 report30 Jul '26 report9% at 16 Nov '2630 Jul '2616 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 20% on 30 Jul 2026, reached 20% on 30 Jul 2026 and reads 9% on 16 Nov 2026. The marks are report dates.

How does MMSI score on business quality?

Merit Medical Systems's overall quality score is 66 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.728.0%ROIC5.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).781.28xFCF / net income1.16x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.6511.7%Revenue growth, trailing0.9%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.390.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.720.84xNet debt / EBITDA2.08x
StabilityDownside volatility of the EBITDA margin over the last five years.442.0 ptsEBITDA margin downside volatility, 5y1.8 pts

How does MMSI compare with similar companies?

The companies in medical instruments & supplies closest to Merit Medical Systems in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ICUI ICU Medical, Inc.$181.87$202.62+11.4%Fairly valued
TFX Teleflex Incorporated$157.10$169.00+7.6%Fairly valued
NVST Envista Holdings Corp$24.03$25.54+6.3%Low evidence grade
ATR AptarGroup, Inc.$143.17$137.10-4.2%Fairly valued
AVTR Avantor, Inc.$15.32$20.70+35.1%Undervalued
RGEN Repligen Corporation$162.78$152.66-6.2%Fairly valued
COO The Cooper Companies, Inc.$61.88$70.88+14.5%Fairly valued
BAX Baxter International Inc.$25.54$24.84-2.7%Fairly valued

What the comparable companies' multiples alone would give for MMSI, the peer-implied price, is $76.05 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

Merit Medical Systems at a glance

Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products.

Market value
$5.2B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$1.7B
Consensus revenue growth, next fiscal year
+8.2%
Analysts with estimates
8
Beta to the US market
0.44
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. MMSI was not among them.

How the fair value is worked out: the model prices Merit Medical Systems on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for MMSI was $82.83. As of 14 Nov 2026 it is $82.63, a change of -0.2%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Merit Medical Systems's valuation

Is Merit Medical Systems stock undervalued or overvalued?

On Faircurve's model, MMSI reads as Fairly valued as of 14 Nov 2026. The model's fair value is $82.63 a share against a last close of $86.35, a gap of -4.3%.

What is MMSI's fair value?

$82.63 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $63.73 to $105.86.

What price range does the model give MMSI?

$77.63 to $96.57 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Merit Medical Systems report earnings next?

The next report is scheduled for 23 Feb 2027. Companies can move their dates.

How much has MMSI moved on past earnings reports?

Across its last 8 reports the median two session move was 3.7%, ignoring direction. The largest was +7.6% around the report of 30 Oct 2025.

How confident is the model in this valuation?

The model's evidence grade for MMSI is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on MMSI

The model holds no idea open on MMSI today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on MMSI with their outcomes. A free account is enough.

Keep reading